Breast Cancer ESMO 2023 Highlights

Rohit Gosain, MD; Rahul Gosain, MD; and Erika P. Hamilton, MD, presenting slides

EP. 1: KEYNOTE-756: Pembrolizumab Plus Chemo in Early-Stage ER+/HER2- Breast Cancer

ByRohit Gosain, MD,Rahul Gosain, MD,Erika P. Hamilton, MD

November 9th 2023

Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.

EP. 2: TROPION-Breast01: Dato-DXd in Metastatic HR+/HER2- Breast Cancer

ByRohit Gosain, MD,Rahul Gosain, MD,Erika P. Hamilton, MD

November 9th 2023

Experts on breast cancer review recent data updates from TROPION-Breast01 on Dato-DXd (datopotamab deruxtecan) in metastatic HR+/HER2- breast cancer.

EP. 3: KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer

ByRohit Gosain, MD,Rahul Gosain, MD,Erika P. Hamilton, MD

November 9th 2023

Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.

EP. 4: Closing Thoughts on Data Updates From ESMO 2023

ByRohit Gosain, MD,Rahul Gosain, MD,Erika P. Hamilton, MD

November 10th 2023

Following their review of data presented at ESMO 2023, the Oncology Brothers offer their key takeaways on the evolving breast cancer treatment landscape.